You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
‘Treat to Target' - Lessons Learnt
Contributor:
Kurti, Zsuzsanna;
Vegh, Zsuzsanna;
Golovics, Petra Anna;
Lakatos, Peter Laszlo
Published:
S. Karger AG, 2016
Published in:
Digestive Diseases, 34 (2016) 1-2, Seite 147-152
Language:
English
DOI:
10.1159/000443131
ISSN:
0257-2753;
1421-9875
Origination:
Footnote:
Description:
<b><i>Background:</i></b> Therapeutic management in inflammatory bowel diseases (IBD) has significantly changed in the last decades with the advent of biological therapy resulting in new treatment targets other than clinical symptoms. <b><i>Key Messages:</i></b> Patient stratification in the early stage of the disease is an important step to identify patients with poor prognosis, who might benefit from early aggressive treatment to avoid complications in the later disease course. Recent randomized and hypothesis driven (e.g., Randomized Evaluation of an Algorithm for Crohn's Treatment, Post-Operative Crohn's Endoscopic Recurrence) clinical trials conducted in the biological era underscore the need of objective disease monitoring including assessment of biomarkers (e.g., C-reactive protein and calprotectin), mucosal healing and, for biologically treated patients, therapeutic drug monitoring beside clinical symptom assessment in both Crohn's disease and ulcerative colitis. <b><i>Conclusions:</i></b> Assessing the treatment efficacy objectively has become an important element of patient monitoring besides clinical symptom assessment. Further clinical studies are needed to assess whether implementation of new therapeutic algorithms based on these targets and tight monitoring in clinical practice have the potential to further improve long-term disease outcomes in IBD.